RNA Therapeutics

GreenLight Biosciences Stock for RNA Therapeutics

The so-called Green Revolution industrialized agriculture, exponentially increasing yields and leading to unprecedented growth of the human population in the process. We’ll let the philosophers debate the wisdom of unleashing more humans on the planet, but the heavy-handed use of chemicals and other methods for strong-arming the land such as tilling and irrigation have taken […]

When Will There Ever Be a Cure for Hepatitis B?

You’ve probably seen the bumper stickers, T-shirts, and memes that declare: “The liver is evil, it must be punished.” We have been known to indulge in a little BDSM with our own meaty organ in a local dive bar or three, hoping that we don’t drink it under the table some day. While there are plenty […]

Moderna Stock Offered in Planned IPO

It’s always kind of comical to see financial pundits make a 50/50 call about some binary outcome in the future and then act like they’re the second coming of Nostradamus when the coin happens to land on heads. In the world of finance, it’s easy to pick one side of an outcome and then bring it up […]

Synlogic Becomes a Synthetic Biology Stock

One downside of having to show up at 8:00 AM every morning to kick off your cushy finance job is all the new language you need to start using. We’re talking about corporate neologisms that try and soften the blow of certain “touchy” terms. Take for example the newly coined term “RIF” which stands for […]

Benitec: A Small RNAi Stock with Big Hopes

In a previous article, we provided a list of 7 publicly traded companies involved in the RNAi Therapeutics space. With the recent IPO of Mirna Therapeutics (NASDAQ:MIRN) and the Benitec listing ADR listing (NASDAQ:BNTC), we can now rebalance our original RNAi therapeutics portfolio for a total of 9 stocks as seen below: When creating this portfolio, […]

Why Moderna Therapeutics Won’t IPO Anytime Soon

We recently wrote an article about 7 publicly traded stocks that are involved in the exciting field of RNA therapeutics or what is often referred to as RNA interference (RNAi). In that article, we noted that not all “RNA therapeutics” companies are created equal and there are actually quite a few categorizations of RNA therapeutics. mRNA is […]

7 RNA Therapeutics Companies to Invest In

RNA therapeutics uses a technology called RNA interference (RNAi) which has rapidly advanced over the past few years and generated a great deal of interest from biotech investors. RNAi is a gene-silencing technology that turns on and off the genes that regulate proteins in people’s cells. Drugs being developed based on this technology have recently advanced, mostly due to improved […]

Argos Therapeutics Helps Kidney Cancer Patients Live Longer

Cancer immunotherapy is a treatment that uses a patient’s own immune cells to attack malignant cancer cells. The treatment involves the creation of antibodies that grab onto target proteins that normally prevent immune cells from attacking cancer. By blocking the activity of these proteins, the immune cell is free to fight the disease. Merck, Roche, GlaxoSmithKline, Bristol-Myers Squibb, and others are […]

A microRNA IPO from Microlin Bio

RNA Interference (RNAi) is a breakthrough in understanding how genes are turned on and off in cells and is widely considered to be one of the most promising and rapidly advancing frontiers in biology and drug development today. The importance of its discovery was recognized by the award of the 2006 Nobel Prize for Physiology or Medicine. […]

RNAi Developer Dicerna Pharmaceuticals to IPO

RNA Interference (RNAi) is a new approach in the development of specific targeted therapies against both rare diseases and cancer. Historically, the pharmaceutical industry has developed two fundamental classes of drugs that can address well-defined targets: small molecules and antibodies. Both of these drug classes have been very successful but are limited in the nature of the […]